X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7858) 7858
Book Chapter (147) 147
Magazine Article (30) 30
Newspaper Article (6) 6
Book / eBook (4) 4
Web Resource (2) 2
Dissertation (1) 1
Newsletter (1) 1
Publication (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6938) 6938
science & technology (6256) 6256
life sciences & biomedicine (6051) 6051
female (4613) 4613
bone density conservation agents - therapeutic use (3660) 3660
bone density conservation agents - adverse effects (3331) 3331
osteoporosis (2828) 2828
male (2737) 2737
aged (2706) 2706
middle aged (2659) 2659
diphosphonates - adverse effects (2139) 2139
bone density conservation agents - administration & dosage (1878) 1878
diphosphonates - therapeutic use (1738) 1738
osteoporosis - drug therapy (1721) 1721
endocrinology & metabolism (1492) 1492
bone density - drug effects (1468) 1468
risk factors (1427) 1427
bisphosphonates (1314) 1314
orthopedics (1302) 1302
medicine & public health (1255) 1255
aged, 80 and over (1249) 1249
animals (1228) 1228
treatment outcome (1164) 1164
fractures (1147) 1147
bones (1082) 1082
osteoporosis, postmenopausal - drug therapy (1079) 1079
diphosphonates - administration & dosage (1054) 1054
adult (1017) 1017
bone density (996) 996
rheumatology (976) 976
dentistry (971) 971
drug therapy (929) 929
care and treatment (914) 914
research (841) 841
bone density conservation agents - pharmacology (807) 807
health aspects (805) 805
abridged index medicus (803) 803
osteonecrosis - chemically induced (801) 801
endocrinology (765) 765
dentistry, oral surgery & medicine (752) 752
bone mineral density (722) 722
surgery (671) 671
analysis (651) 651
general & internal medicine (630) 630
oncology (616) 616
medicine, general & internal (587) 587
denosumab (571) 571
imidazoles - adverse effects (564) 564
bone neoplasms - secondary (554) 554
jaw diseases - chemically induced (550) 550
zoledronic acid (550) 550
bisphosphonate (544) 544
pharmacology & pharmacy (521) 521
diphosphonates (515) 515
fractures, bone - prevention & control (512) 512
retrospective studies (507) 507
drug administration schedule (493) 493
osteoporosis - prevention & control (486) 486
bone neoplasms - drug therapy (480) 480
alendronate - adverse effects (476) 476
density (473) 473
postmenopausal women (471) 471
time factors (465) 465
imidazoles - therapeutic use (451) 451
complications and side effects (447) 447
vitamin d (442) 442
administration, oral (440) 440
alendronate - therapeutic use (437) 437
bone remodeling - drug effects (428) 428
phosphonates (414) 414
internal medicine (410) 410
cancer (406) 406
follow-up studies (403) 403
double-blind method (380) 380
dosage and administration (374) 374
clinical trials (370) 370
alendronate (363) 363
osteoporotic fractures - prevention & control (355) 355
osteoporosis - chemically induced (351) 351
imidazoles - administration & dosage (332) 332
breast neoplasms - drug therapy (330) 330
necrosis (330) 330
rats (329) 329
bone and bones - drug effects (327) 327
absorptiometry, photon (317) 317
breast cancer (307) 307
prospective studies (307) 307
prevention (300) 300
osteonecrosis (298) 298
diphosphonates - pharmacology (294) 294
alendronate - administration & dosage (290) 290
glucocorticoids - adverse effects (290) 290
risk assessment (276) 276
dose-response relationship, drug (274) 274
radiography (270) 270
osteoporosis - complications (269) 269
biomarkers - blood (250) 250
adolescent (242) 242
medicine, research & experimental (241) 241
vitamin d - therapeutic use (241) 241
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7711) 7711
Japanese (171) 171
German (86) 86
French (83) 83
Spanish (51) 51
Danish (21) 21
Dutch (19) 19
Portuguese (18) 18
Chinese (16) 16
Polish (15) 15
Hungarian (14) 14
Italian (10) 10
Russian (9) 9
Norwegian (8) 8
Czech (3) 3
Swedish (3) 3
Croatian (2) 2
Hebrew (2) 2
Arabic (1) 1
Korean (1) 1
Persian (1) 1
Romanian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 08/2009, Volume 361, Issue 8, pp. 745 - 755
.... This study investigated the effects of denosumab on bone mineral density and fractures in men receiving androgen-deprivation therapy for prostate cancer... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lumbar Vertebrae - injuries | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Male | Osteoporosis - drug therapy | Prostatic Neoplasms - physiopathology | Bone Remodeling - drug effects | Incidence | Antibodies, Monoclonal, Humanized | Spinal Fractures - prevention & control | RANK Ligand - pharmacology | Injections, Subcutaneous | Aged, 80 and over | RANK Ligand - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Lumbar Vertebrae - physiology | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Osteoporosis - chemically induced | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Prostatic Neoplasms - surgery | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Denosumab | Bone Density Conservation Agents - pharmacology | Orchiectomy | Bone Density - drug effects | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Fractures, Bone - prevention & control | Osteoporosis | Bone density | Prostate cancer | Older people | Men | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2014, Volume 370, Issue 5, pp. 412 - 420
This study shows that in postmenopausal women with low bone mineral density, the monoclonal antibody romosozumab, which binds to sclerostin, an osteoblast-activity inhibitor, was associated... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biomarkers - metabolism | Teriparatide - pharmacology | Teriparatide - therapeutic use | Bone Density Conservation Agents - adverse effects | Drug Administration Schedule | Antibodies, Monoclonal - pharmacology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Lumbar Vertebrae - drug effects | Bone Density Conservation Agents - administration & dosage | Bone Remodeling - drug effects | Osteoporosis, Postmenopausal - drug therapy | Alendronate - therapeutic use | Bone Density Conservation Agents - pharmacology | Calcium - blood | Bone Density - drug effects | Antibodies, Monoclonal - administration & dosage | Injections, Subcutaneous | Alendronate - pharmacology | Aged, 80 and over | Least-Squares Analysis | Female | Aged | Osteoporosis | Care and treatment | Analysis | Monoclonal antibodies | Bones | Dosage and administration | Postmenopausal women | Research | Drug therapy | Density | Femur | Spine (lumbar) | SOST protein | Bone turnover | Bisphosphonates | Hip | Post-menopause | Bone resorption | Alendronic acid | Bone growth | Bone mass | Parathyroid hormone | Older people | Bone mineral density | Bone density | Osteogenesis | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2017, Volume 377, Issue 15, pp. 1417 - 1427
... that binds to and inhibits sclerostin, with a dual effect of increasing bone formation and decreasing bone resorption. 3 , 4 In a randomized, controlled trial, 5 1 year... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Risk | Bone Remodeling - drug effects | Alendronate - therapeutic use | Incidence | Spinal Fractures - prevention & control | Female | Drug Therapy, Combination | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Least-Squares Analysis | Aged | Cardiovascular Diseases - chemically induced | Fractures, Bone - prevention & control | Treatment outcome | Care and treatment | Fractures | Growth | Analysis | Monoclonal antibodies | Bones | Research | Jaw | Femur | Vertebrae | Immunoglobulins | Inhibitor drugs | Osteonecrosis | SOST protein | Bisphosphonates | Hip | Post-menopause | Bone resorption | Osteoporosis | Alendronic acid | Bone growth | Bone density | Drug therapy | Osteogenesis | Index Medicus | Abridged Index Medicus | randomized-trial | metaanalysis | disease | postmenopausal women | strength | bone-mineral density | Klinisk medicin | vertebral fractures | sclerosteosis | Clinical Medicine | aorta | risk
Journal Article
The New England journal of medicine, ISSN 1533-4406, 02/2009, Volume 360, Issue 7, pp. 679 - 691
Journal Article
Annals of internal medicine, ISSN 0003-4819, 02/2008, Volume 148, Issue 3, pp. 197 - 213
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2012, Volume 367, Issue 18, pp. 1714 - 1723
.... 3 Mortality after osteoporotic fracture is higher among men than among women. 2 , 4 Previous studies involving men with osteoporosis have focused on the surrogate outcomes of bone mineral density and bone-turnover markers, 5... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Male | Osteoporosis - drug therapy | Risk | Osteoporosis - etiology | Spinal Fractures - prevention & control | Aged, 80 and over | Diphosphonates - therapeutic use | Imidazoles - therapeutic use | Testosterone - blood | Diphosphonates - adverse effects | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Imidazoles - adverse effects | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Logistic Models | Imidazoles - pharmacology | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Analysis of Variance | Hypogonadism - complications | Aged | Diphosphonates - pharmacology | Drugs | Dose-response relationship (Biochemistry) | Osteoporosis | Men | Zoledronic acid | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Risk factors | Vertebrae | Intravenous administration | Calcium | Clinical trials | Bone turnover | Hypogonadism | Serum levels | Testosterone | Fractures | Vitamin D | Older people | Bone mineral density | Bone density | Supplementation | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 09/2015, Volume 386, Issue 9999, pp. 1147 - 1155
Journal Article